We are live on ! Find out more
TWST icon

Twist Bioscience

245 hedge funds and large institutions have $2.99B invested in Twist Bioscience in 2024 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 92 increasing their positions, 77 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more call options, than puts

Call options by funds: $5.94M | Put options by funds: $2.02M

19% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 77

0.55% less ownership

Funds ownership: 113.33%112.78% (-0.55%)

6% less funds holding

Funds holding: 262245 (-17)

8% less capital invested

Capital invested by funds: $3.25B → $2.99B (-$264M)

32% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 50

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
245
Holders Change
-17
Holders Change %
-6.49%
% of All Funds
3.52%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
34
Increased
92
Reduced
77
Closed
50
Calls
$5.94M
Puts
$2.02M
Net Calls
+$3.91M
Net Calls Change
-$1.05M
Name Holding Trade Value Shares
Change
Change in
Stake
EI
251
EAM Investors
California
-$3.19M -64,764 Closed
ECU
252
Eisler Capital (US)
New York
-$1.99M -40,438 Closed
SAM
253
Simplify Asset Management
Nevada
-$1.26M -25,471 Closed
AIMCA
254
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
-$1.11M -22,531 Closed
BCM
255
Bayesian Capital Management
New York
-$1.03M -20,846 Closed
CIA
256
Capital Impact Advisors
Massachusetts
-$1M -20,380 Closed
PCM
257
Penserra Capital Management
California
-$938K -19,026 Closed
ONGA
258
O'Neil Global Advisors
California
-$810K -16,436 Closed
NRD
259
Nebula Research & Development
New York
-$735K -14,905 Closed
PAS
260
Point72 Asia (Singapore)
Singapore
-$664K -13,480 Closed
CANY
261
Caxton Associates (New York)
New York
-$590K -11,963 Closed
TCM
262
Teza Capital Management
Illinois
-$571K -11,584 Closed
SFC
263
Strategic Financial Concepts
Texas
-$202 -11,286 Closed
PVI
264
Pura Vida Investments
New York
-$493K -10,000 Closed
BHCM
265
Brevan Howard Capital Management
Jersey
-$485K -9,836 Closed
PD
266
Point72 (DIFC)
United Arab Emirates
-$328K -6,662 Closed
LOAMU
267
Lombard Odier Asset Management (USA)
New York
-$307K -6,221 Closed
SSA
268
Schonfeld Strategic Advisors
New York
-$281K -5,706 Closed
Calamos Advisors
269
Calamos Advisors
Illinois
-$281K -5,694 Closed
BFM
270
Boothbay Fund Management
New York
-$246K -5,000 Closed
PP
271
Paloma Partners
Connecticut
-$243K -4,930 Closed
CC
272
Centiva Capital
New York
-$229K -4,651 Closed
Capstone Investment Advisors
273
Capstone Investment Advisors
New York
-$212K -4,299 Closed
AWM
274
Axxcess Wealth Management
California
-$205K -4,167 Closed
DekaBank Deutsche Girozentrale
275
DekaBank Deutsche Girozentrale
Germany
-$61K -1,287 Closed

TWST Hedge Fund Activity: Q3 2024 in Review

245 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q3 2024, worth a combined $2.99B — down 8.1% from $3.25B a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of TWST and 34 opened new positions — a net loss of 16 holders — while 77 trimmed existing stakes and 92 added.

The largest buyer was Thrivent Financial for Lutherans, opening a new position worth an estimated $46.3M. The largest seller was ARK Investment Management, cutting an estimated $36.7M.

  • 245 institutional investors held Twist Bioscience (TWST) as of Q3 2024, down from 262 in Q2 2024.
  • Funds reported $2.99B of Twist Bioscience stock for Q3 2024, down 8.1% quarter-over-quarter.
  • 34 funds opened new Twist Bioscience positions in Q3 2024 and 50 closed out, a net change of -16 holders.
  • The largest Twist Bioscience buyer in Q3 2024 was Thrivent Financial for Lutherans, an estimated $46.3M added.
  • The largest Twist Bioscience seller in Q3 2024 was ARK Investment Management, an estimated $36.7M sold.

Based on aggregated 13F filings for Q3 2024.